<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-01-28</title>
    <style>
        :root, [data-theme="minimal"] {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        [data-theme="pharma-blue"] {
            --bg-primary: #f0f4f8;
            --bg-secondary: #ffffff;
            --text-primary: #2d3748;
            --text-secondary: #718096;
            --accent: #2b6cb0;
            --accent-hover: #2c5282;
            --border: #e2e8f0;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            --header-bg: linear-gradient(135deg, #1a365d 0%, #2b6cb0 100%);
            --header-text: #ffffff;
        }

        [data-theme="warm"] {
            --bg-primary: #faf8f5;
            --bg-secondary: #ffffff;
            --text-primary: #451a03;
            --text-secondary: #78716c;
            --accent: #d97706;
            --accent-hover: #b45309;
            --border: #e7e5e4;
            --card-shadow: 0 1px 3px 0 rgba(0, 0, 0, 0.1);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Theme Switcher */
        .theme-switcher {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 8px;
            background: var(--bg-secondary);
            padding: 8px;
            border-radius: 12px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
        }

        .theme-btn {
            width: 32px;
            height: 32px;
            border: 2px solid transparent;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s ease;
            position: relative;
        }

        .theme-btn:hover {
            transform: scale(1.1);
        }

        .theme-btn.active {
            border-color: var(--accent);
        }

        .theme-btn[data-theme="minimal"] {
            background: linear-gradient(135deg, #ffffff 50%, #0071e3 50%);
        }

        .theme-btn[data-theme="pharma-blue"] {
            background: linear-gradient(135deg, #1a365d 50%, #2b6cb0 50%);
        }

        .theme-btn[data-theme="warm"] {
            background: linear-gradient(135deg, #faf8f5 50%, #d97706 50%);
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <!-- Theme Switcher -->
    <div class="theme-switcher">
        <button class="theme-btn active" data-theme="minimal" title="ç®€çº¦ç™½"></button>
        <button class="theme-btn" data-theme="pharma-blue" title="åŒ»è¯è“"></button>
        <button class="theme-btn" data-theme="warm" title="æš–è‰²è°ƒ"></button>
    </div>

    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-01-28 <span style="font-size: 14px; opacity: 0.7;">(US Eastern / EST)</span></p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">104</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-01-29 04:06</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-22">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">01/22</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-23">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">01/23</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-24">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/24</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-25">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">01/25</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-26">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">01/26</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-27">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">01/27</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-28">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">01/28</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>ä»Šæ—¥æ¦‚è§ˆ</h4>
<p>ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºåŸºå› ç¼–è¾‘ä¸ç»†èƒæ²»ç–—é¢†åŸŸçš„é‡è¦è¿›å±•ï¼Œå…¶ä¸­Intelliaçš„CRISPRç–—æ³•ä¸´åºŠè¯•éªŒéƒ¨åˆ†æ¢å¤ä»¥åŠCellareså®Œæˆ2.57äº¿ç¾å…ƒèèµ„ä¸ºè¡Œä¸šäº®ç‚¹ã€‚åŒæ—¶ï¼Œå¼ºç”Ÿæ——ä¸‹Darzalex Fasproè·å¾—FDAæ–°é€‚åº”ç—‡æ‰¹å‡†ï¼Œå·©å›ºå…¶åœ¨å¤šå‘æ€§éª¨é«“ç˜¤æ²»ç–—é¢†åŸŸçš„åœ°ä½ã€‚æ­¤å¤–ï¼Œç¤¼æ¥ä¸Seamless Therapeuticsè¾¾æˆè¶…10äº¿ç¾å…ƒåŸºå› ç¼–è¾‘åˆä½œï¼Œæ˜¾ç¤ºå‡ºå¤§å‹è¯ä¼æŒç»­åŠ ç é—ä¼ åŒ»å­¦é¢†åŸŸã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>2. FDA lifts hold on an Intellia CRISPR drug trial</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ<br>
   - FDAè§£é™¤å¯¹Intelliaå…³é”®CRISPRåŸºå› ç¼–è¾‘ç–—æ³•ä¸´åºŠè¯•éªŒçš„éƒ¨åˆ†æš‚åœï¼Œæ ‡å¿—ç€åŸºå› ç¼–è¾‘é¢†åŸŸç›‘ç®¡çš„é‡è¦è¿›å±•</p>
<p><strong>3. FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - FDAæ‰¹å‡†Darzalex Fasproè”åˆç–—æ³•ç”¨äºæ–°è¯Šæ–­å¤šå‘æ€§éª¨é«“ç˜¤ï¼Œä¸ºæ‚£è€…æä¾›é‡è¦æ–°æ²»ç–—é€‰æ‹©</p>
<p><strong>5. Cellares raises $257M to fund global expansion as it eyes 2027 IPO</strong> â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - ç»†èƒç–—æ³•åˆ¶é€ å•†Cellareså®Œæˆ2.57äº¿ç¾å…ƒDè½®èèµ„ï¼Œä¸º2027å¹´IPOåšå‡†å¤‡ï¼Œæ˜¾ç¤ºç»†èƒæ²»ç–—é¢†åŸŸæŒç»­å—èµ„æœ¬é’ç</p>
<p><strong>6. Lilly partners with recombinase-based gene editing startup Seamless Therapeutics</strong> â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - ç¤¼æ¥ä¸é‡ç»„é…¶åŸºå› ç¼–è¾‘åˆåˆ›å…¬å¸è¾¾æˆè¶…11äº¿ç¾å…ƒåˆä½œï¼Œè¿›ä¸€æ­¥å¸ƒå±€é—ä¼ åŒ»å­¦é¢†åŸŸ</p>
<p><strong>14. Regenxbio gene therapy trials suspended by FDA over safety worries</strong> â­â­â­â­<br>
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ<br>
   - FDAå› å®‰å…¨æ€§é—®é¢˜æš‚åœRegenxbioä¸¤é¡¹åŸºå› ç–—æ³•è¯•éªŒï¼Œå‡¸æ˜¾åŸºå› æ²»ç–—å®‰å…¨æ€§ç›‘ç®¡çš„é‡è¦æ€§</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>æ–°è¯ç ”å‘</strong> (Drug R&D): ä»Šæ—¥æ–°è¯ç ”å‘åŠ¨æ€åŒ…æ‹¬siRNAç–—æ³•BWâ€‘20829è¿›å…¥IIbæœŸè¯•éªŒã€ç½—æ°å±•ç¤ºGLP-1æ³¨å°„å‰‚æ–°æ•°æ®ã€ä»¥åŠå¤šç§åŸºå› ç¼–è¾‘å’Œç»†èƒæ²»ç–—æŠ€æœ¯çš„è¿›å±•ï¼Œæ˜¾ç¤ºè¡Œä¸šæŒç»­å‘ç²¾å‡†åŒ»ç–—å’Œå…ˆè¿›ç–—æ³•è½¬å‹ã€‚<br>
<strong>ä¸´åºŠè¯•éªŒ</strong> (Clinical Trials): ä¸´åºŠè¯•éªŒé¢†åŸŸå‡ºç°é‡è¦ç›‘ç®¡å˜åŒ–ï¼ŒIntelliaçš„CRISPRç–—æ³•è¯•éªŒéƒ¨åˆ†æ¢å¤ï¼Œè€ŒRegenxbioçš„åŸºå› ç–—æ³•è¯•éªŒå› å®‰å…¨æ€§é—®é¢˜è¢«æš‚åœï¼Œå‡¸æ˜¾ä¸´åºŠè¯•éªŒä¸­é£é™©ä¸ç›‘ç®¡çš„å¹³è¡¡ã€‚</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>éœ€å…³æ³¨FDA/MHRA/Health Canadaå°†äº2æœˆ6æ—¥ä¸¾è¡Œçš„ç›‘ç®¡ç ”è®¨ä¼šï¼Œä¼šè®®å°†è®¨è®ºè‰¯å¥½ä¸´åºŠå®è·µã€ç”Ÿç‰©ç­‰æ•ˆæ€§å’Œè¯ç‰©è­¦æˆ’ç­‰è®®é¢˜ï¼Œå¯èƒ½å½±å“æœªæ¥ä¸´åºŠè¯•éªŒè®¾è®¡å’Œç›‘ç®¡è¦æ±‚ã€‚åŒæ—¶ï¼Œæ¬§ç›Ÿä¸å°åº¦è‡ªç”±è´¸æ˜“åå®šä¸­å…³äºè¯å“å‡ºå£å…³ç¨çš„è°ˆåˆ¤è¿›å±•å€¼å¾—å…³æ³¨ï¼Œå¯èƒ½å½±å“å…¨çƒåˆ¶è¯ä¾›åº”é“¾æ ¼å±€ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">42 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Responding to tougher FDA standards, Recipharm debuts new facility for beta-lactam drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 09:13</span>
                        
                        <span class="news-importance">â­â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Juggling a mix of customer demand and new regulations, Recipharm has built out a new facility in Bengaluru, India, to produce nonbacterial beta-lactam tablets. By commissioning the plant, Recipharm says it has lassoed up a â€œmajor partnershipâ€ with an unnamed, â€œleading innovative biopharmaceutical companyâ€ to help produce the partner&#39;s non-bacterial beta-lactam tablets.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/fda-winds-changing-recipharm-debuts-purpose-built-plant-beta-lactam-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Antheia seals 2nd series C funding close, hitting more than $175M in a year
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 08:26</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia&#39;s total funding over the past year to more than $175 million when combined with other capital and new contracts with the U.S. government, according to the company.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/antheia-seals-second-close-series-c-funding-hit-175m-year" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        J&amp;amp;J sharpens Darzalex&#39;s edge with quadruplet FDA nod in newly diagnosed multiple myeloma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 18:23</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A new FDA nod for autologous stem cell transplant-ineligible patients fortifies Darzalex Faspro&#39;s position for patients with newly diagnosed multiple myeloma.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jjs-darzalex-faspro-expands-its-first-line-offerings-fda-nod-quadruplet-multiple-myeloma" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        EU looks to knock out pharmaceutical export tariffs in sweeping free trade pact with India
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 11:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Nearly two decades after the parties first floated the idea of a free trade agreement, the turbulence of the global market has prompted the European Union and India to carry their deal across the finish line.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/eu-looks-knock-out-pharmaceutical-export-tariffs-sweeping-free-trade-pact-india" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Medicare drug prices, the EU-India trade deal, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-28 14:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/28/medicare-pharma-india-europe-novo-lilly-advertising/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about pharma lobbying, an FDA gene-editing pathway, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-26 14:05</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The pharmaceutical industry, long one of the most powerful lobbies in Washington, is spending more than ever to influence the nationâ€™s capital</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/26/pharma-lobbying-novo-genes-fda-patents/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about drug shortages, llama antibodies for developing meds, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 14:27</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in 2024</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/23/moderna-vaccines-cigna-shortages-cancer-obesity-weight/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: The number of new drug shortages in U.S. hits lowest level in 20 years, but myriad problems remain
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 17:40</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in the beginning of 2024.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/22/medicines-pharma-biotech-shortages-hospitals-injectables/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Teva taps â€˜SNLâ€™ alum Will Forte to join Huntingtonâ€™s disease awareness push
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 15:42</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Following in the footsteps of Phathom Pharmaceuticals&#39; and Allergan Aestheticsâ€™ own partnerships with â€œSaturday Night Liveâ€ stars, Teva Pharmaceuticals is turning to a famous funnyman to tackle a not-so-funny topic.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/teva-taps-snl-alum-will-forte-join-huntingtons-disease-awareness-push" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Arcutis, Kowa part ways on US marketing partnership for Zoryve
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 11:15</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The companies had committed to a five-year partnership in July 2024, in which Kowa agreed to promote the topical treatment to primary care physicians to extend the med&#39;s reach beyond dermatologists.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/arcutis-kowa-cut-ties-two-years-us-marketing-partnership-arcutis-topical-zorvye" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 11:55</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/anti-vaccine-sentiment-pushes-moderna-away-new-late-stage-infectious-disease-trials" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about a Roche obesity drug, a clash over 340B claims data, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-27 14:17</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after the drug led to significant weight loss in a mid-stage trial</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/27/roche-obesity-menopause-china-lilly-340b-hospitals-bausch/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The new rules of biopharma M&amp;amp;A: 4 trends driving dealmaking this year
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 13:36</span>
                        
                    </div>
                    
                    <p class="news-summary">As biopharma M&amp;amp;A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and commercialization process.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/new-rules-biopharma-ma-4-trends-driving-deal-making-year" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Advocacy group files FOIA lawsuit to gain further clarity on Trump administration&#39;s MFN pricing deals
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 15:28</span>
                        
                    </div>
                    
                    <p class="news-summary">Consumer advocacy organization Public Citizen has filed a Freedom of Information Act lawsuit against the Department of Health and Human Services and the Department of Commerce&amp;nbsp;for failing to provide documents related to President Donald Trumpâ€™s most-favored nation drug pricing deals with Pfizer and Eli Lilly.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/public-citizen-files-foia-lawsuits-against-trump-administration-mfn-pricing-deals-pfizer" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Halozyme catches M&amp;amp;A wave to snap up Surf Bio in delivery tech deal worth up to $400M
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 12:05</span>
                        
                    </div>
                    
                    <p class="news-summary">Shortly after acquiring Elektrofi to beef up its subcutaneous drug delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/halozyme-catches-ma-wave-snap-surf-bio-delivery-tech-deal-worth-400m" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        American Academy of Pediatrics&#39; updated immunization schedule rebukes CDC&#39;s drastic cutbacks
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 13:15</span>
                        
                    </div>
                    
                    <p class="news-summary">The pediatric medical group recommends children be vaccinated against 18 diseases, as opposed to the federal government&#39;s recent reduction to 11.</p>
                    
                    <a href="https://www.fiercepharma.com/providers/american-academy-pediatrics-updated-immunization-schedule-rebukes-cdcs-drastic-changes" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Teva, after third straight year of growth, expects downturn in 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 11:01</span>
                        
                    </div>
                    
                    <p class="news-summary">With a third consecutive year of sales growth under its belt, the company is expecting flat or slightly down revenues in 2026, it said.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/teva-third-year-growth-innovative-products-expects-downturn-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ro serves up Super Bowl GLP-1 campaign starring Serena Williams
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 10:58</span>
                        
                    </div>
                    
                    <p class="news-summary">Ro is bringing Serena Williams to the Super Bowl. Months after partnering with Williams, Ro has secured airtime at Super Bowl LX to showcase how the 23-time Grand Slam tennis championâ€™s life changed after taking GLP-1 drugs sourced from the telehealth company.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/ro-serves-serena-williams-super-bowl-glp-1-campaign" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Cellares&#39; series D round draws $257M as cell therapy contractor takes operations global
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-28 08:52</span>
                        
                    </div>
                    
                    <p class="news-summary">With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, raising $257 million in a series D round.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/cellares-series-d-round-draws-257m-it-readies-commercial-production" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Boehringer Super Bowl ad recruits Octavia Spencer, SofÃ­a Vergara for mission to boost kidney testing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 14:38</span>
                        
                    </div>
                    
                    <p class="news-summary">Boehringer Ingelheimâ€™s mission for Super Bowl LX viewers, should they choose to accept it, is to learn more about urine albumin-to-creatinine ratio screening to monitor kidney health in people with certain risk factors.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/boehringer-super-bowl-ad-recruits-octavia-spencer-sofia-vergara-mission-boost-kidney" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump administration rolls out 15 more high-profile drugs for IRA price negotiations
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 17:14</span>
                        
                    </div>
                    
                    <p class="news-summary">Even as the Trump administration works to implement its most-favored-nation pricing system, the U.S. government continues to advance efforts to negotiate Medicare drug prices as enabled by the Inflation Reduction Act.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trump-administration-rolls-out-15-more-high-profile-drugs-ira-price-negotiations" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        China regulators suspend sale of Sun Pharma&#39;s dementia med after site inspection
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 11:13</span>
                        
                    </div>
                    
                    <p class="news-summary">Chinaâ€™s National Medical Products Administration suspended the import, sale and use of Sun&#39;s rivastigmine hydrogen tartrate capsules after a virtual site inspection uncovered manufacturing shortfalls.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/chinese-regulators-suspend-sale-sun-pharmas-dementia-med-after-site-inspection" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Servier delivers 16% revenue jump, firming up â‚¬10B ambition by 2030
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 10:09</span>
                        
                    </div>
                    
                    <p class="news-summary">After posting 16.2% revenue growth in the last financial year, Servier President Olivier Laureau said the company has moved â€œone important step closerâ€ to achieving an ambitious goal for 2030.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/servier-delivers-16-revenue-jump-firming-eu10b-ambition-2030" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer retains top spot in vaccine maker rankings as Sanofi&#39;s slide sparks &#39;code red&#39; call
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 10:06</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer again heads up a physician ranking of vaccine manufacturers, beating Merck &amp;amp; Co. and Moderna to complete an unchanged top three from the last edition of the survey. But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good standing with physicians.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/pfizer-retains-top-spot-vaccine-rankings-sanofis-slide-sparks-code-red-call" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Siegfried extends M&amp;amp;A streak, gaining 3 sites from SK Capital and advancing US onshoring aims
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-27 09:47</span>
                        
                    </div>
                    
                    <p class="news-summary">Siegfried has signed agreements to acquire the controlled drug substance businesses of the Noramco Group and Extractas Bioscience. With the deals, Siegfried gains API sites in Wilmington, Delaware; Athens, Georgia; and Australia.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/siegfried-continues-its-ma-splurge-gaining-3-sites-sk-capital" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Catalent moves to wind down operations at EU cell therapy manufacturing hub
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 15:01</span>
                        
                    </div>
                    
                    <p class="news-summary">Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it&#39;s planning to wind down cell therapy manufacturing operations in the town.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/catalent-moves-wind-down-operations-eu-cell-therapy-manufacturing-hub" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        New rules, higher stakes: Biopharma plays the long game in 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 13:20</span>
                        
                    </div>
                    
                    <p class="news-summary">While 2025 was dedicated to â€œunderstanding a little bit more about the rules of this game that weâ€™re playing,â€ 2026 is all about being active players in the game, McKinsey senior partner Greg Graves said Jan. 13 at Fierce JPM Week.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/new-rules-higher-stakes-biopharma-plays-long-game-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-26 10:28</span>
                        
                    </div>
                    
                    <p class="news-summary">With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. But the road to market leadership is growing more complex as the two AstraZeneca-partnered brands move into earlier lines of therapy while facing intensifying competition.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/daiichi-sankyo-navigates-complexity-success-enhertu-datroway-push-market-dominance" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly battles weight stigma in short film centering obesity conversation on health, not appearance
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 11:52</span>
                        
                    </div>
                    
                    <p class="news-summary">GLP-1 giant Eli Lilly has once again taken to the medium of short film to get an important message about obesity across.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/lilly-battles-weight-stigma-short-film-centering-obesity-conversation-health-not" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Eli Lilly expands work on gene therapies for hearing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-28 14:49</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/28/biotech-news-eli-lillly-expands-gene-therapy-for-hearing/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: More high-income countries have used compulsory licenses to gain access to meds, study finds
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-28 13:00</span>
                        
                    </div>
                    
                    <p class="news-summary">More high-income countries have used compulsory licenses to gain access to meds, study finds.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/28/pharma-compulsory-licenses-patents-medicines-wto/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Startup Altido Therapeutics pursues CAR-T for glioblastoma tumors
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-28 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Glioblastoma is almost always fatal. Altido Bio is trying to commercialize a CAR-T cell therapy that has shown rare promise.</p>
                    
                    <a href="https://www.statnews.com/2026/01/28/gene-therapy-nick-leschly-startup-altido-therapeutics-targets-glioblastoma/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: New startup to develop a GLP-1 drug for addiction
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-27 14:40</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/27/biotech-news-glp-1-drug-for-addiction-startup/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Roche moves obesity drug to pivotal trials after mid-stage success
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-27 08:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Roche plans to launch pivotal studies of an experimental weight loss drug after a successful mid-stage trial.</p>
                    
                    <a href="https://www.statnews.com/2026/01/27/roche-ct388-trials-weight-loss-obesity/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-26 21:11</span>
                        
                    </div>
                    
                    <p class="news-summary">The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of the 340B drug discount program.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/26/pharma-lilly-medicines-hospitals-340b/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Launch of Wegovy pill looks to be going strong so far
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-26 14:30</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/26/biotech-news-wegovy-pill-launch-holds-promise-novo-nordisk/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 17:19</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/23/pharma-biotech-jobs-teva-novartis-novo-lilly/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Insurers blame drugmakers, hospitals for high prices
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 15:26</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus more biotech news updates, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/23/biotech-news-insurers-blame-drugmakers-hospitals-for-prices/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Health insurance execs shift blame for costly, confusing health care system
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 20:11</span>
                        
                    </div>
                    
                    <p class="news-summary">Health insurance execs blame the high cost of health care on hospitals, doctors, and prescription drugs.</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/health-insurance-execs-blame-high-costs-hospitals-doctors-pharma/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: France rebuffs Trump over drug-pricing boast
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 15:58</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news from The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/biotech-news-2/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Europeâ€™s pharma supply chain, stopping GLP-1 drugs, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 14:26</span>
                        
                    </div>
                    
                    <p class="news-summary">Many patients using GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, an analysis of real-world data shows</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/22/europe-insulin-novo-weight-cvs-pharmacies/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Anthony Letai says NCI is more stable than perceived and is heading for a big year
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Anthony Letai says the National Cancer Institute is more stable than perceived and is heading for a big year.</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/national-cancer-institute-director-anthony-letai-q-and-a/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA lifts hold on an Intellia CRISPR drug trial
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-27 16:59</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.</p>
                    
                    <a href="https://www.biopharmadive.com/news/intellia-fda-lifts-hold-nex-z-crispr-ttr-amyloidosis/810584/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Cellares raises $257M to fund global expansion as it eyes 2027 IPO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 12:00</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Clinical-stage cell therapy manufacturer Cellares has raised $257 million in a Series D round as it gears up commercially and prepares to go public. Cellares aims to launch its commercial cell therapy manufacturing services in ...</p>
                    
                    <a href="https://endpoints.news/cellares-raises-257m-to-fund-global-expansion-as-it-eyes-2027-ipo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly partners with recombinase-based gene editing startup Seamless Therapeutics
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 12:00</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Seamless Therapeutics, a startup developing a new form of gene editing based on enzymes called recombinases, has struck a partnership with Eli Lilly that could be worth more than $1.12 billion, the company announced Wednesday ...</p>
                    
                    <a href="https://endpoints.news/lilly-partners-with-startup-developing-recombinase-based-gene-editing/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA lifts hold on one of two Phase 3 gene editing studies by Intellia
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 15:52</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia</p>
                    
                    <a href="https://endpoints.news/fda-lifts-hold-on-one-of-two-phase-3-gene-editing-studies-by-intellia/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly bets on Seamless, delving further into genetic medicine for hearing loss
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-28 19:09</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.</p>
                    
                    <a href="https://www.biopharmadive.com/news/eli-lilly-seamless-deal-gene-editing-hearing-loss/810694/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Regenxbio gene therapy trials suspended by FDA over safety worries
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-28 16:06</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing and a treatment for Hunter syndrome nearing an FDA decision.</p>
                    
                    <a href="https://www.biopharmadive.com/news/regenxbio-fda-hold-hunter-hurler-syndrome-gene-therapy/810691/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Roche, trailing in obesity, showcases new data for GLP-1 shot
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-27 16:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.</p>
                    
                    <a href="https://www.biopharmadive.com/news/roche-obesity-drug-phase-2-data-carmot-glp-gip/810578/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        An immune drug developer raises $50M to finance its eczema drug testing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-27 15:53</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.</p>
                    
                    <a href="https://www.biopharmadive.com/news/trex-bio-series-b-extension-atopic-dermatitis/810617/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Chinaâ€™s edge in early-stage drugmaking â€˜likely to persist,â€™ Pitchbook says
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-26 19:15</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.</p>
                    
                    <a href="https://www.biopharmadive.com/news/china-biotech-drug-licensing-trends-pitchbook-cell-gene-therapy/810478/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biotech investor Cormorant secures $150M for another SPAC deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-26 14:43</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid a rebound in SPAC activity, the prolific &amp;ldquo;crossover&amp;rdquo; investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.</p>
                    
                    <a href="https://www.biopharmadive.com/news/cormorant-helix-iii-spac-deal-biotech-merger-ipo/810436/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Oral Rogaine maker Veradermics looks to raise $181M from IPO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 19:18</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Veradermics, a biotech in late-stage testing with an oral version of Rogaine, is looking to raise $181.8 million in net proceeds from its proposed IPO. The Connecticut biotech will garner that amount if it sells ...</p>
                    
                    <a href="https://endpoints.news/oral-rogaine-maker-veradermics-looks-to-raise-181m-from-ipo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA asks court to pause Louisiana&#39;s abortion pill fight
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 19:18</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration is asking a federal court to halt a case over the abortion pill mifepristone while the FDA undertakes a review of the drugâ€™s safety protocols. An ongoing mifepristone review could result in ...</p>
                    
                    <a href="https://endpoints.news/fda-asks-court-to-pause-louisianas-abortion-pill-fight/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA suspends two Regenxbio gene therapy trials after patient developed brain tumor
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 15:56</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has placed studies of two gene therapies from Regenxbio on hold after a five-year-old patient in one of the trials was found to have a brain tumor. The drug regulator&#39;s decision is a ...</p>
                    
                    <a href="https://endpoints.news/fda-suspends-regenxbio-gene-therapy-trials-after-patient-developed-brain-tumor/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Eikon seeks $273M IPO with pipeline led by Chinese cancer drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 15:25</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A biotech led by former Merck top brass with a pipeline anchored by three cancer drugs linked to Chinese drug developers is pushing ahead with an IPO, even while off its peak valuation. Eikon Therapeutics ...</p>
                    
                    <a href="https://endpoints.news/eikon-seeks-273m-ipo-with-pipeline-led-by-chinese-cancer-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biopharma Sentiment Index | Q1 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 12:45</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric. After four years of hunkering down, the mood in biopharma turned sharply more optimistic heading into ...</p>
                    
                    <a href="https://endpoints.news/biopharma-sentiment-index-q1-2026/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 11:59</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Boehringer Ingelheimâ€™s experimental pill has shown signs of improving kidney function in patients with a rare renal condition in a mid-stage trial. But the data are somewhat confusing, with the lowest dose working better than ...</p>
                    
                    <a href="https://endpoints.news/boehringer-ingelheim-takes-rare-kidney-disease-drug-to-phase-3-despite-puzzling-mid-stage-data/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Cardiff execs depart as company drops mixed Phase 2 data
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 18:22</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Shares {$CRDF} of Cardiff Oncology fell more than 30% after the biotech disclosed mixed Phase 2 data and announced the departure of two of its top executives. San Diego-based Cardiff</p>
                    
                    <a href="https://endpoints.news/cardiff-execs-depart-as-company-drops-mixed-phase-2-data/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Insilicoâ€™s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 15:40</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Insilico Medicine is having quite a month. Fresh from deals with Servier and Hygtia Therapeutics, the biotech has signed a new collaboration with Shanghai-based Qilu Pharmaceutical worth nearly ...</p>
                    
                    <a href="https://endpoints.news/insilicos-latest-deal-is-a-120m-cardiometabolic-drug-discovery-pact-with-qilu-pharma/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 14:31</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about Vial, Skyhawk and Gimv: AstraZeneca stops cardio drug: The UK pharma giant has terminated a Phase 1 of an oral cardio drug candidate called AZD0233, according ...</p>
                    
                    <a href="https://endpoints.news/astrazeneca-ends-work-on-cardio-drug-lisata-and-qilu-terminate-deal/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs for cancer, arthritis and HIV on Medicareâ€™s list for 2028 price cuts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-28 16:51</span>
                        
                    </div>
                    
                    <p class="news-summary">Still, the medications in the latest round of negotiations &amp;mdash; which now includes &amp;ldquo;Part B&amp;rdquo; drugs given in doctors offices &amp;mdash; draw very limited revenue from Medicare, an analyst pointed out.</p>
                    
                    <a href="https://www.biopharmadive.com/news/medicare-drug-price-2028-trulicity-biktarvy-verzenio-kisqali/810688/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Halozyme buys a biotech startup; Cytokinetics launches heart drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-28 16:20</span>
                        
                    </div>
                    
                    <p class="news-summary">Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst wrote. Elsewhere, Boehringer dipped into China for a bispecific drug and a trans-Atlantic VC firm restocked.</p>
                    
                    <a href="https://www.biopharmadive.com/news/halozyme-surf-myqorzo-boehringer-china-gsk-rsv-epidarex/810539/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sarepta, battling slowing sales, claims Duchenne gene therapyâ€™s impact grows with time
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-26 16:46</span>
                        
                    </div>
                    
                    <p class="news-summary">On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help &amp;ldquo;rebalance the discussion&amp;rdquo; surrounding Elevidys.</p>
                    
                    <a href="https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-embark-data/810461/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ChenMed CEO warns against GLP-1s for seniors
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 23:12</span>
                        
                    </div>
                    
                    <p class="news-summary">ChenMed CEO Chris Chen said the primary care chain isnâ€™t encouraging the use of GLP-1 drugs for weight loss after finding the medications led to worse health outcomes among its older patients. Speaking on a ...</p>
                    
                    <a href="https://endpoints.news/chenmed-ceo-warns-against-glp-1s-for-seniors/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Round three of IRA negotiations is expected to be â€˜manageableâ€™ for pharma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 21:19</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to criticize the Biden-era program. On Tuesday, CMS</p>
                    
                    <a href="https://endpoints.news/round-three-of-ira-negotiations-is-expected-to-be-manageable-for-pharma/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lonza still intends to sell its capsules and health ingredients business
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 18:51</span>
                        
                    </div>
                    
                    <p class="news-summary">More than a year after Lonza announced it will sell its capsules and health business, the Swiss CDMO said it has yet to finalize the deal with a buyer. A spokesperson said it has multiple ...</p>
                    
                    <a href="https://endpoints.news/lonza-still-intends-to-sell-its-capsules-and-health-ingredients-business/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Teva CEO says it has successfully transitioned into a biopharma company
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 17:18</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/teva-ceo-says-it-has-successfully-transitioned-into-a-biopharma-company/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        HHS seeks to protect drugmakers from violating anti-kickback laws ahead of TrumpRx launch
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 15:26</span>
                        
                    </div>
                    
                    <p class="news-summary">With launch time potentially approaching for TrumpRx, HHS unveiled part of its plan to shield drugmakers from anti-kickback laws to allow them to sell their products on the new direct-to-consumer platform. The guidance â€” released via ...</p>
                    
                    <a href="https://endpoints.news/hhs-seeks-to-protect-drugmakers-from-anti-kickback-laws-ahead-of-trumprx-launch/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Included Health launches alternative health plan
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 15:02</span>
                        
                    </div>
                    
                    <p class="news-summary">Included Health, the virtual care and navigation company, is now offering a health plan for employers. Itâ€™s new territory for the startup, and the move puts it in a league with companies such as Centivo ...</p>
                    
                    <a href="https://endpoints.news/included-health-launches-alternative-health-plan/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Hengrui blazes trail as Chinese drugmakers aspire to go multinational
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 15:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Jiangsu Hengrui Pharmaceuticals has quietly become a top 25 biopharma company in the world by market value. Once virtually unknown outside of China, the company has made its name overseas via an R&amp;amp;D engine that ...</p>
                    
                    <a href="https://endpoints.news/hengrui-blazes-trail-as-chinese-drugmakers-aspire-to-go-multinational/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Halozyme buys drug delivery biotech Surf Bio; Sanofi backs Sensorion
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-28 14:39</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/halozyme-buys-drug-delivery-biotech-surf-bio-sanofi-backs-sensorion/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Updated: CMS picks Lillyâ€™s Trulicity, Gilead&#39;s Biktarvy for third round of Medicare negotiations
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 22:26</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/cms-picks-lillys-trulicity-for-third-round-of-medicare-negotiations/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Hospitals could earn more for buying US-made drugs, CMS proposes
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 20:05</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration&#39;s Centers for Medicare &amp;amp; Medicaid Services is looking to incentivize hospitals to buy more domestically-produced drugs. Under a proposed rule, hospitals purchasing more than 50% of domestic-made essential ...</p>
                    
                    <a href="https://endpoints.news/hospitals-could-earn-more-for-buying-us-made-drugs-cms-proposes/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UnitedHealth projects lower revenue in 2026 as it resets its business
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 18:11</span>
                        
                    </div>
                    
                    <p class="news-summary">UnitedHealth Groupâ€™s turnaround plan to trade membership for improved profit margins will result in lower revenue in 2026, as the healthcare giant attempts to recover from a disastrous period of setbacks that ...</p>
                    
                    <a href="https://endpoints.news/unitedhealth-projects-lower-revenue-in-2026-as-it-resets-its-business/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Virtual womenâ€™s health company Wisp buys TBD Health
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-27 14:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Wisp, a womenâ€™s telehealth company, bought sexual healthcare startup TBD Health, as virtual care companies look to become more comprehensive in the services they offer. Terms of the deal, which closed near ...</p>
                    
                    <a href="https://endpoints.news/virtual-womens-health-company-wisp-buys-tbd-health/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 19:37</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Oncology (Cancer)/Hematologic Malignancies Approval Notifications
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 17:55</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA does not&amp;nbsp;issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to&amp;nbsp;Drugs@FDA&amp;nbsp;for the latest approvals and prescribing information for specific products.</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA/MHRA/Health Canada Symposium: Regulatory perspectives in good clinical practice, bioequivalence and good pharmacovigilance practice - 06/02/2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 15:26</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This symposium will highlight current and emerging topics of interest to the industry related to good clinical practice, bioequivalence and good pharmacovigilance practice.</p>
                    
                    <a href="http://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fdamhrahealth-canada-symposium-regulatory-perspectives-good-clinical-practice-bioequivalence-and" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Medication Health Fraud for Specific Diseases and Conditions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-28 19:11</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA has identified condition-specific medication health fraud scams that can pose significant risks to consumers.</p>
                    
                    <a href="http://www.fda.gov/drugs/medication-health-fraud/medication-health-fraud-specific-diseases-and-conditions" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs@FDA Data Files
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-28 16:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        A Special Year, New Seal, and Renewed Commitment to the American People
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-28 14:55</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has unveiled an official agency seal which signifies the many public health strides made over 120 years.</p>
                    
                    <a href="http://www.fda.gov/news-events/fda-voices/special-year-new-seal-and-renewed-commitment-american-people" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Untitled Letters
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 20:21</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion&#39;s untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.</p>
                    
                    <a href="http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Project Orbis
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 20:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Information Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE) that provides a framework for concurrent submission and review of oncology products among international partners.</p>
                    
                    <a href="http://www.fda.gov/about-fda/oncology-center-excellence/project-orbis" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What Does FDA Approve? Part 2
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 19:23</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The growing spread of rumors, misinformation and disinformation about science, medicine, and the FDA, is putting patients and consumers at risk. FDA is here to provide the facts.</p>
                    
                    <a href="http://www.fda.gov/consumers/consumer-updates/what-does-fda-approve-part-2" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s New Related to Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 17:56</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Want to know what&#39;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patient Listening Session Summaries
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 21:44</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.</p>
                    
                    <a href="http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drugs Program Monthly and Quarterly Activities Report
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 18:25</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Monthly and quarterly metrics of the FDA Generic Drugs Program.</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drugs-program-monthly-and-quarterly-activities-report" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biosimilar Product Information
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 18:16</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This page includes a chart of the approved biosimilar and interchangeable products. The approval of biosimilar products can improve access to care for patients by increasing the number of medication options and potentially lower costs.</p>
                    
                    <a href="http://www.fda.gov/drugs/biosimilars/biosimilar-product-information" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 15:06</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This guidance is the third in a series of four methodological patient-focused drug development guidances that describe how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers to be used for product development decision-making.</p>
                    
                    <a href="http://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-26 15:04</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">This draft guidance provides guidance to sponsors and applicants submitting investigational new drug applications (INDs), new drug applications (NDAs), biologics licensing applications (BLAs), or supplemental applications on the appropriate use of Bayesian methods in clinical trials.</p>
                    
                    <a href="http://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-28 20:52</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patent Certifications and Suitability Petitions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 19:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Information on patents and suitability petitions that impact the availability of generic drugs.</p>
                    
                    <a href="http://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 17:22</span>
                        
                    </div>
                    
                    <p class="news-summary">This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Center For Immunology Science, LLC - 719933 - 01/13/2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 14:20</span>
                        
                    </div>
                    
                    <p class="news-summary">Sponsor/Investigator</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/center-immunology-science-llc-719933-01132026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Fulijaya Manufacturing SDN. BHD. - 719172 - 01/14/2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-27 14:20</span>
                        
                    </div>
                    
                    <p class="news-summary">CGMP/Finished Pharmaceuticals/Adulterated</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fulijaya-manufacturing-sdn-bhd-719172-01142026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">8 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Argo Biopharma doses first patient in phase 2b trial of BWâ€‘20829
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-28 14:20</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">siRNA therapeutic progresses in global study for patients with elevated Lp(a)</p>
                    
                    <a href="https://pharmatimes.com/news/argo-biopharma-doses-first-patient-in-phase-2b-trial-of-bw-20829/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Otsuka Pharmaceuticalâ€™s Dawnzera receives EC approval for hereditary angioedema prevention
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-26 12:05</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo</p>
                    
                    <a href="https://pharmatimes.com/news/otsuka-pharmaceuticals-dawnzera-receives-ec-approval-for-hereditary-angioedema-prevention/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ErVimmune raises 17m euros in funding to develop cancer vaccine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-22 14:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The vaccine could be created as a ready-to-use product, rather than needing to be personalised</p>
                    
                    <a href="https://pharmatimes.com/news/ervimmune-raises-17m-euros-in-funding-to-develop-cancer-vaccine/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BioMed X launches kidney disease project in partnership with the government of Barbados
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-27 13:54</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Initiative focuses on population-specific molecular profiling</p>
                    
                    <a href="https://pharmatimes.com/news/biomed-x-launches-kidney-disease-project-in-partnership-with-the-government-of-barbados/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-28">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Akari files new patent and advances second ADC targeting CEACAM5
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-28 14:15</span>
                        
                    </div>
                    
                    <p class="news-summary">Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate</p>
                    
                    <a href="https://pharmatimes.com/news/akari-files-new-patent-and-advances-second-adc-targeting-ceacam5/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-27">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Gedeon Richter UK takes over UK rights to cariprazine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-27 13:47</span>
                        
                    </div>
                    
                    <p class="news-summary">Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati</p>
                    
                    <a href="https://pharmatimes.com/news/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-26">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Corcept Therapeuticsâ€™ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-26 11:57</span>
                        
                    </div>
                    
                    <p class="news-summary">Ovarian cancer is the fifth leading cause of deaths from cancer in women</p>
                    
                    <a href="https://pharmatimes.com/news/corcept-therapeutics-relacorilant-plus-nab-paclitaxel-shows-positive-results-in-ovarian-cancer/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-22 12:36</span>
                        
                    </div>
                    
                    <p class="news-summary">The PM Awards celebrate creativity in pharmaceutical marketing and healthcare communications</p>
                    
                    <a href="https://pharmatimes.com/news/book-your-tickets-and-join-the-pm-society-for-the-40th-pm-awards-on-20-march-2026/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-01-29 04:06</p>
        </footer>
    </div>

    <script>
    (function() {
        // ========== Theme Switcher ==========
        const themeBtns = document.querySelectorAll('.theme-btn');
        const savedTheme = localStorage.getItem('pharma-daily-theme') || 'minimal';

        function setTheme(theme) {
            document.body.setAttribute('data-theme', theme);
            themeBtns.forEach(btn => {
                btn.classList.toggle('active', btn.getAttribute('data-theme') === theme);
            });
            localStorage.setItem('pharma-daily-theme', theme);
        }

        // Apply saved theme on load
        setTheme(savedTheme);

        themeBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                setTheme(this.getAttribute('data-theme'));
            });
        });

        // ========== Date Filter ==========
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>